Abciximab (ReoPro)

General information

Class/mechanism: the Fab fragment of the chimeric human-murine monoclonal antibody 7E3, which binds to the glycoprotein IIb/IIIa receptor on platelets, preventing them from binding to fibrinogen, von Willebrand factor, and other adhesion molecules and thereby inhibiting platelet aggregation.
Route: IV
Extravasation: n/a

For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.

History of changes in FDA indication

• 1994-12-22: Initial approval (label not available at Drugs @ FDA)

Also known as

• Brand names: Clotinab, ReoPro